Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Non-Current Assets (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Non-Current Assets over the past 15 years, most recently at $153.7 million for Q2 2025.

  • For Q2 2025, Non-Current Assets fell 11.14% year-over-year to $153.7 million; the TTM value through May 2025 reached $653.3 million, down 3.2%, while the annual FY2025 figure was $153.7 million, 11.14% down from the prior year.
  • Non-Current Assets for Q2 2025 was $153.7 million at Lifecore Biomedical, Inc. \De\, roughly flat from $153.5 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $356.6 million in Q2 2021 and troughed at $153.5 million in Q1 2025.
  • A 5-year average of $199.6 million and a median of $169.6 million in 2023 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: soared 161.44% in 2021 and later plummeted 55.68% in 2022.
  • Year by year, Non-Current Assets stood at $270.8 million in 2021, then tumbled by 42.05% to $156.9 million in 2022, then increased by 7.78% to $169.1 million in 2023, then increased by 2.62% to $173.5 million in 2024, then fell by 11.45% to $153.7 million in 2025.
  • Business Quant data shows Non-Current Assets for LFCR at $153.7 million in Q2 2025, $153.5 million in Q1 2025, and $173.5 million in Q4 2024.